Received: 20 January 2020
Accepted: 10 June 2020
First Online: 19 June 2020
Compliance with ethical standards
: YV, SO, CT and PB: consulting fees from BMS, MSD, Pfizer, Novartis, Ipsen, Roche, Astellas, Sanofi, Janssen. DB: funding to institution for clinical research, advisory role or travel accommodation: Bristol-Meyers Squibb, Pfizer, Roche, Ipsen, MSD, Astra-Zeneca. No potential conflicts of interest were disclosed by the other authors.
: The study was approved by the local institutional review board and was conducted with Good Clinical Practice Guidelines and the Declaration of Helsinki. All patients gave their oral consent. CNIL declaration No 2215794 v 0
: Informed consent for publication has been obtained.